<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499768</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZY14</org_study_id>
    <nct_id>NCT04499768</nct_id>
  </id_info>
  <brief_title>A Longitudinal Study of Choroidal Changes After Cataract Surgery in Eyes With Diabetic Retinopathy</brief_title>
  <official_title>A Longitudinal Study of Choroidal Changes Assessed With Swept-source Optical Coherence Tomography After Cataract Surgery in Eyes With Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the influence of phacoemulsification on choroidal vasculature in patients with&#xD;
      diabetic retinopathy (DR) undergoing cataract surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the influence of phacoemulsification on choroidal vasculature in patients with&#xD;
      diabetic retinopathy (DR) undergoing cataract surgery through the follow-up of choroidal&#xD;
      thickness (CT) and choroidal vascularity index (CVI) using swept-source optical coherence&#xD;
      tomography (SS-OCT) system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CVI at baseline</measure>
    <time_frame>CVI was assessed at baseline(within 1 week before surgery)</time_frame>
    <description>choroidal vascularity index(CVI) was defined as the proportion of vascular area to total circumscribed area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CVI at 1 week postoperatively</measure>
    <time_frame>CVI was assessed 1 week after surgery.</time_frame>
    <description>choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CVI at 1 month postoperatively</measure>
    <time_frame>CVI was assessed 1 month after surgery.</time_frame>
    <description>choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CVI at 3 months postoperatively</measure>
    <time_frame>CVI was assessed 3 months after surgery.</time_frame>
    <description>choroidal vascularity index (CVI)was defined as the proportion of vascular area to total circumscribed area.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT at baseline</measure>
    <time_frame>CT was assessed at baseline and 1 week, 1 month, 3 month after surgery.</time_frame>
    <description>Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT at 1 week postoperatively</measure>
    <time_frame>CT was assessed at 1 week after surgery.</time_frame>
    <description>Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT at 1 month postoperatively</measure>
    <time_frame>CT was assessed at 1 month after surgery.</time_frame>
    <description>Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT at 3 months postoperatively</measure>
    <time_frame>CT was assessed at 3 months after surgery.</time_frame>
    <description>Choroid thickness (CT) was the thickness of the choroidal layer, CT values were obtained with the built-in software of the SS-OCT device.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VD at baseline</measure>
    <time_frame>VD of the choriocapillaris was assessed at baseline.</time_frame>
    <description>VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VD at 1 week postoperatively</measure>
    <time_frame>VD of the choriocapillaris was assessed 1 week after surgery.</time_frame>
    <description>VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VD at 1 month postoperatively</measure>
    <time_frame>VD of the choriocapillaris was assessed 1 month after surgery.</time_frame>
    <description>VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VD at 3 months postoperatively</measure>
    <time_frame>VD of the choriocapillaris was assessed 3 months after surgery.</time_frame>
    <description>VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP at baseline</measure>
    <time_frame>IOP was assessed at baseline and 1 week, 1 month, 3 month after surgery.</time_frame>
    <description>IOP was the value of intraocular pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP at 1 week postoperatively</measure>
    <time_frame>IOP was assessed 1 week after surgery.</time_frame>
    <description>IOP was the value of intraocular pressure .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP at 1 month postoperatively</measure>
    <time_frame>IOP was assessed 1 month after surgery.</time_frame>
    <description>IOP was the value of intraocular pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP at 3 months postoperatively</measure>
    <time_frame>IOP was assessed 3 months after surgery.</time_frame>
    <description>IOP was the value of intraocular pressure .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA at baseline</measure>
    <time_frame>BCVA was assessed at baseline .</time_frame>
    <description>BCVA was the best corrected visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCVA at 3 months postoperatively</measure>
    <time_frame>BCVA was assessed 3 months after surgery.</time_frame>
    <description>BCVA was the best corrected visual acuity.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">46</enrollment>
  <condition>Optical Coherence Tomography</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Choroid</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>the age-related cataract patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DR group</arm_group_label>
    <description>the cataract patients with mild/moderate NPDR</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        23 eyes of 23 cataract patients with mild/moderate NPDR without DME, and 23 age-matched&#xD;
        non-diabetic patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  agedâ©¾40years; intraocular pressure (IOP) &lt; 21 mm Hg in both eyes, spherical refractive&#xD;
             error&lt;6 diopters spherical equivalent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous retinal surgery, glaucoma, uveitis, age-related macular degeneration,&#xD;
             arterial or vein occlusions, macular hole, or other ocular diseases that could&#xD;
             interfere the CT and/or CVI measurement, severe systemic diseases, such as&#xD;
             uncontrolled hypertension, obstructive sleep apnea, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Xi Shen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Xi Shen</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <keyword>Diabetic choroidopathy</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>choroidal vascularity index</keyword>
  <keyword>choroidal thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

